Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Toll-Like Receptors (TLRs) agonists in prostate cancer remain investigational and are best understood as a double-edged approach: some TLR agonists, especially TLR3 and TLR7-directed agents, have shown antitumor activity, while stimulation of other pathways such as TLR4 or TLR9 in prostate cancer cells may promote invasion, inflammation, or treatment resistance
…